IMUX: Immunic, Inc.
About
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Current Value
$1.061 Year Return
Current Value
$1.061 Year Return
Key Details
Market Cap
$94.58M
P/E Ratio
-0.85
1Y Stock Return
-1.41%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include IMUX
Stock's related to IMUX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGEN | 40.52% | $228.91M | -28.00% | 0.00% |
| ALEC | 37.64% | $377.04M | -19.46% | 0.00% |
| FOLD | 37.39% | $2.84B | -11.52% | 0.00% |
| GPRO | 36.93% | $179.52M | -67.23% | 0.00% |
| CLFD | 36.44% | $398.66M | +4.48% | 0.00% |
| CHPT | 35.45% | $487.69M | -42.64% | 0.00% |
| RVMD | 35.12% | $9.50B | +171.62% | 0.00% |
| CDXS | 34.77% | $345.86M | +121.35% | 0.00% |
| EDIT | 34.62% | $204.72M | -75.49% | 0.00% |
| CRBU | 34.60% | $180.20M | -62.45% | 0.00% |
| GCO | 33.83% | $331.05M | -4.72% | 0.00% |
| PSTX | 33.68% | $269.98M | +6.13% | 0.00% |
| CAAP | 33.14% | $3.17B | +55.32% | 0.00% |
| AKRO | 32.98% | $2.17B | +93.09% | 0.00% |
| GSAT | 32.95% | $3.29B | +19.18% | 0.00% |
| GNE | 32.38% | $425.67M | -37.42% | 1.92% |
| VPG | 32.26% | $279.20M | -30.23% | 0.00% |
| SPCE | 32.02% | $196.64M | -84.01% | 0.00% |
| WS | 31.57% | $2.22B | +75.00% | 1.09% |
| TPIC | 31.54% | $96.08M | -13.30% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OKLO | -0.01% | $2.66B | +111.04% | 0.00% |
| MVO | 0.02% | $106.15M | -22.78% | 16.78% |
| EE | 0.03% | $747.78M | +68.74% | 0.33% |
| MMC | -0.04% | $108.41B | +10.89% | 1.37% |
| POST | -0.08% | $6.45B | +28.40% | 0.00% |
| UL | -0.08% | $143.25B | +21.40% | 3.25% |
| IFRX | -0.11% | $113.06M | +31.51% | 0.00% |
| SPR | -0.13% | $3.72B | +23.27% | 0.00% |
| CLX | -0.15% | $20.81B | +20.66% | 2.88% |
| NOC | 0.17% | $71.54B | +4.23% | 1.60% |
| AEE | -0.17% | $24.59B | +20.10% | 2.87% |
| MPC | 0.18% | $51.04B | +7.57% | 1.57% |
| K | -0.23% | $27.77B | +52.50% | 2.79% |
| BEST | 0.34% | $31.65M | +3.88% | 0.00% |
| PRT | -0.36% | $48.72M | -16.56% | 10.33% |
| TR | 0.38% | $2.33B | -0.74% | 1.10% |
| RYAN | 0.40% | $8.81B | +55.63% | 0.62% |
| JNPR | 0.40% | $11.61B | +30.55% | 2.49% |
| MO | 0.41% | $94.67B | +37.05% | 7.07% |
| AIFU | -0.46% | $67.49M | -83.02% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -15.83% | $78.15B | +35.51% | 0.42% |
| CHD | -15.75% | $27.18B | +19.50% | 1.03% |
| CL | -13.94% | $76.48B | +22.25% | 2.12% |
| COR | -12.21% | $47.48B | +21.20% | 0.86% |
| CME | -10.54% | $82.76B | +9.21% | 1.98% |
| CBOE | -9.96% | $21.46B | +15.84% | 1.11% |
| PGR | -9.75% | $149.10B | +57.29% | 0.45% |
| PG | -9.47% | $402.15B | +14.14% | 2.33% |
| KSPI | -9.14% | $20.86B | +18.06% | 3.37% |
| PM | -8.91% | $201.41B | +39.59% | 4.05% |
| TCTM | -8.45% | $8.10M | -42.99% | 0.00% |
| OXBR | -8.37% | $19.05M | +178.18% | 0.00% |
| SJM | -7.91% | $11.91B | -0.25% | 3.82% |
| NAPA | -6.98% | $1.63B | +9.61% | 0.00% |
| KR | -6.73% | $42.03B | +35.08% | 2.11% |
| KO | -6.42% | $269.63B | +7.86% | 3.07% |
| EXC | -6.30% | $39.29B | +0.57% | 3.88% |
| LMT | -6.17% | $126.40B | +18.99% | 2.36% |
| MNOV | -6.07% | $93.19M | +2.15% | 0.00% |
| KMB | -6.01% | $45.22B | +11.57% | 3.58% |
ETF's related to IMUX
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -38.12% | $388.04M | 1.43% |
| VIXY | -23.76% | $195.31M | 0.85% |
| USDU | -19.38% | $201.97M | 0.5% |
| UUP | -15.51% | $309.25M | 0.77% |
| CTA | -15.44% | $350.27M | 0.78% |
| TAIL | -12.09% | $67.98M | 0.59% |
| CLOI | -11.47% | $715.40M | 0.4% |
| EQLS | -11.41% | $76.08M | 1% |
| IBHD | -7.84% | $327.80M | 0.35% |
| KCCA | -7.83% | $220.51M | 0.87% |
| KMLM | -7.71% | $353.87M | 0.9% |
| TBLL | -7.71% | $1.92B | 0.08% |
| DBE | -7.54% | $50.13M | 0.77% |
| HDRO | -4.65% | $164.26M | 0.3% |
| BILZ | -4.45% | $563.02M | 0.14% |
| FMF | -3.23% | $244.61M | 0.95% |
| DBO | -2.96% | $217.57M | 0.77% |
| SOYB | -2.19% | $27.32M | 0.22% |
| XBIL | -1.86% | $637.70M | 0.15% |
| XHLF | -1.45% | $874.27M | 0.03% |
News
Yahoo
Investors who take an interest in Immunic, Inc. ( NASDAQ:IMUX ) should definitely note that the Independent Director...
Yahoo
Immunic (IMUX) announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. The first two portions of the phase 1 clinical trial, Parts A and B, were single ascending dose and multiple ascending dose, double-blind, placebo-controlled studies in a total of 71 healthy human subjects. Single and multiple ascendi
Yahoo
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. James Daveson, Gastroen
Yahoo
Immunic Inc (IMUX) reports promising clinical trial advancements and strategic partnerships, despite increased R&D expenses and market competition.
SeekingAlpha
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ETCompany ParticipantsJessica Breu - Vice President Investor Relations...
SeekingAlpha
The following slide deck was published by Immunic, Inc.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.